Search 

Our clients are early-stage biotechnology, medical device, diagnostics and pharmaceutical service companies. When we begin working with a client they are frequently looking to complete proof-of-concept studies, secure intellectual property and other critical preliminary tasks. Typically we raise the first round ($1 - $5 million of capital) needed to accomplish these milestones, usually, but not always from angel investors. After key milestones have been achieved using that money, we generally follow by raising a second round of $5-20 million, usually institutional money, for development and growth

By working this way, we increase our clients' success rate raising capital and building their companies and the returns to the investors we bring into those companies. We have raised over $80 million in early stage funding for our clients (in Seed, Series A and Series B rounds) and delivered realized returns, so far, over $500 million—a realized return to date of over 6X—to the investors who provided that early stage capital, with a number of the companies still driving towards an exit that may increase that figure. Realized (cash-on-cash) internal rates of return for a hypothetical investor who participated in each round of financing offered by WG&A to date exceeds 65% annually.

Wellington Partners is a venture capital firm based in Munich, Germany, with an additional office in Zurich, Switzerland. The firm specializes in early-stage and growth capital investments in the Technology and Life Sciences sector. The firm has approximately €800M AUM and is currently investing out of a €100M fund for Life Science companies. Depending on the stage of the company, the firm can allocate up to €10M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndicates. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

Western Oncolytics is developing a novel immunotherapy to treat a wide range of solid tumors.  Our therapy is an oncolytic vector with multiple therapeutic transgenes that both stimulate the immune system and remove local tumor immune inhibition.  The vector is engineered to avoid the immune system itself, thus overcoming a major drawback in competing designs.  It is the only therapy in the world with these leading attributes.  Western Oncolytics' therapy works in combination with other treatments, e.g. checkpoint inhibitors, and is capable of systemic (intravenous) delivery. 

Our team comprises the leading scientists, clinicians, and regulatory experts within our field, including entrepreneurs who successfully exited companies with earlier technologies.  In comparison animal testing measuring tumor growth and survival, our therapy performed far better than earlier, clinically-proven oncolytic therapies.

Western Oncolytics is currently raising investment to complete preclinical development and a planned clinical trial. 

Westwood & Wilshire is a premier provider of executive search services to the Pharmaceutical, Biotechnology, Medical Devices and Diagnostics sectors.  Services include:

-Direct Hire Executive Search
-Interim Executive Search and Consultant Placement
-Board of Director and Advisory Group Development

Our clients range from Venture Capital-backed portfolio start ups to Fortune 500 Big Pharma. Our success encompasses executive level placements across Clinical, Medical, Regulatory, R&D, Quality and Commercial.

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.